Table 2 Clinical characteristics of RA patients
Variables | Group I (n = 30) | Group II (n = 30) | Test of Sig. | p-value |
|---|---|---|---|---|
Duration of illness (years) | ||||
 Range | 2.0–45.0 | 0.50–30.0 | U =  366.0 | 0.212 |
 Median (IQR) | 10.50 (5.0–18.0) | 8.0 (4.0–15.0) | ||
Duration of Sjogren manifestations (month) | ||||
 Range | 1.0–36.0 | – | – | – |
 Median (IQR) | 6.0 (3.0–12.0) | – | ||
Xerophthalmia (n, %) | 30(100) | 0(0) | -- | -- |
 Xerostomia (n, %) | 30(100) | 0(0) | -- | -- |
 Keratoconjunctivitis sicca (n, %) | 24(80) | 0(0) | -- | -- |
 Positive salivary gland biopsy (n, %) | 10(33.3) | 0(0) | -- | -- |
 Positive Saxon test (n, %) | 27(90) | 0(0) |  |  |
Morning stiffness (min.) | ||||
 Range | 30.0–120.0 | 30.0–120.0 | U =  386.50 | 0.305 |
 Median (IQR) | 55.0 (30.0–80.0) | 50.0 (30.0–70.0) | ||
Tender joints | Â | Â | Â | Â |
 Range | 0.0–28.0 | 0.0–28.0 | U =  416.0 | 0.614 |
 Median (IQR) | 8.0 (1.0–15.0) | 7.0 (1.0–13.0) | ||
Swollen joints | Â | Â | Â | Â |
 Range | 0.0–5.0 | 0.0–6.0 | U =  383.50 | 0.240 |
 Median (IQR) | 4.0 (0.0–8.0) | 3.0 (0.0–6.0) | ||
VAS | Â | Â | Â | Â |
 Range | 10.0–80.0 | 10.0–100.0 | U =  433.0 | 0.798 |
 Median (IQR) | 40.0 (30.0–60.0) | 30.0 (20.0–60.0) | ||
DAS28 | ||||
 Range | 1.66–7.03 | 1.50–7.36 | T= 0.705 | 0.483 |
 Mean ± SD. | 4.19 ± 1.53 | 3.91 ± 1.53 |  |  |
m HAQ | ||||
 Range | 0.0–2.28 | 0.0–2.28 | U =  427.0 | 0.731 |
 Median (IQR) | 1.5 (0.1–2.28) | 1.4 (0.1–2.28) |  |  |